Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Preoperative Combination of Pembrolizumab and Radiation Therapy in Patients With Operable Breast Cancer

Trial Profile

Preoperative Combination of Pembrolizumab and Radiation Therapy in Patients With Operable Breast Cancer

Status: Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 06 Nov 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pembrolizumab (Primary) ; Antineoplastics
  • Indications Adenocarcinoma; Early breast cancer; HER2 negative breast cancer; Triple negative breast cancer
  • Focus Therapeutic Use
  • Acronyms PEARL
  • Most Recent Events

    • 23 Sep 2023 Primary endpoint (Number of Patients Who do Not Necessitate a Delay in Standard of Care Treatment After Receiving the Investigational Combination of Preoperative Pembrolizumab and Radiation) has been met according to results presented at the CRI-ENCI-AACR: 7th Annual International Cancer, Immunotherapy Conference.
    • 23 Sep 2023 Results presented at the CRI-ENCI-AACR: 7th Annual International Cancer, Immunotherapy Conference
    • 25 May 2023 Planned End Date changed from 21 Apr 2023 to 21 Apr 2025.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top